Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital

Current Medical Research and Opinion

Volumn 20, Issue 4, 2004, Pages 469-476

  Rapp, Robert P ^a,b   Evans, Martin E ^b   Martin, Craig ^a   Ofotokum, Igho ^b   Empey, Kerry L ^a   Armitstead, John A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bacterial susceptibility; Cost effectiveness; Fluoroquinolones

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE;

ANTIBIOTIC SENSITIVITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; COST CONTROL; DRUG COST; DRUG FORMULARY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MORTALITY; PHOTOTOXICITY; QT PROLONGATION; SIDE EFFECT; SKIN MANIFESTATION; TORSADE DES POINTES; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BACTERIA; CIPROFLOXACIN; COST SAVINGS; DRUG COSTS; FLUOROQUINOLONES; FORMULARIES, HOSPITAL; HOSPITAL COSTS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; ORGANIZATIONAL POLICY;

EID: 1942470497     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003223     Document Type: Conference Paper

References (34)

1. Bertino JS Jr. Integrating fluoroquinolones into the hospital formulary. Pharmacotherapy 2001;21:273S-83S
2. Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health-Syst Pharm 2002;59:529-33
3. Walker SE, Martin WR, Franke TR. Costs and bacterial susceptibility after therapeutic interchange of fluoroquinolones. Am J Health-Syst Pharm 2000;57:1711-2
4. Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health-Syst Pharm 2000;57:S17-S21
5. Clark LC, Davis CW. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health-Syst Pharm 2000;57:S10-S13
6. Glemaud I. Use of a physician order entry system to identify opportunities for intravenous to oral levofloxacin conversion. Am J Health-Syst Pharm 2000;57:S14-S16
7. Bartlett JG, Dowell SF, Mandell LA, File TM Jr., Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82
8. Cunha BA. Quinolones: clinical use and formulary considerations. Adv Ther 1998;15:277-87
9. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Chn Infect Dis 2002;34:1047-54
10. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001;48:375-81
11. Evans ME. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. Eur J Clin Microbiol Infect Dis 2001;20:883-5
12. Rapp RP, Ribes JA, Overman SB, Darkow TE, Evans ME. A decade of antimicrobial susceptibilities at the university of kentucky hospital. Ann Pharmacother 2002;36:596-604
13. Zhanel GG, Ennis K, Vercaigne LJ, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13-59
14. Drusano G, Labro M-T, Cars OF, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infection 1998;4(Suppl. 2):2S27-41
15. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-3
16. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;1:459-63
17. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21:253S-72S
18. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593-6
19. Owens RC, Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:301-19
20. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72
21. Owens RC Jr., Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663-8
22. Bertino JS Jr., Owens RC Jr., Carnes TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002;34:861-3
23. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med 2002;113:45S-54S
24. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc 2002;287:2215-20
25. Paladino JA. Pharmacoeconomics of antimicrobial therapy. Am J Health-Syst Pharm 1999;56:S25-S28
26. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Pharmacotherapy 2001;21:89S-94S
27. Palmer CS, Zhan C, Elixhauser A, Halpern MT, Rance L, Feagan BG, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000;22:250-64
28. Wong-Beringer A, Nguyen K-H, Razeghi J. Implementing a program for switching from i.v. to oral antimicrobial therapy. Am J Health Syst Pharm 2001;58:1146-9
29. Sullivan JG, McElroy AD, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy: treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999;20:S49-S59
30. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001;45:2358-62
31. Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537-41
32. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52:51-5
33. Richard GA, Childs SJ, Fowler CL, Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharm Ther 1998;23:534-40
34. Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics 1998;13:35-49